Show simple item record

dc.contributor.authorGumus, Mahmut
dc.contributor.authorMastey, Vera
dc.contributor.authorHarnett, James
dc.contributor.authorSezer, Ahmet
dc.contributor.authorChen, Chieh-I
dc.contributor.authorCicin, Irfan
dc.contributor.authorTurk, Haci M.
dc.contributor.authorGogishvili, Miranda
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorBondarenko, Igor
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorIvanescu, Cristina
dc.contributor.authorNaumann, Ulrike
dc.contributor.authorReaney, Matthew
dc.contributor.authorKonidaris, Gerasimos
dc.contributor.authorSasane, Medha
dc.contributor.authorBrady, Keri
dc.contributor.authorLi, Siyu
dc.contributor.authorGullo, Giuseppe
dc.contributor.authorRietschel, Petra
dc.date.accessioned2021-11-30T20:59:21Z
dc.date.available2021-11-30T20:59:21Z
dc.date.issued2021-05-01T00:00:00Z
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29674
dc.subjectGumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Harnett J., et al., -Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.titlePatient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
dc.typeArticle
dc.identifier.wosWOS:000708120605058
dc.identifier.doi10.1200/jco.2021.39.15_suppl.9078
local.publication.isinternational1


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record